350 related articles for article (PubMed ID: 31515250)
21. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
Kiladjian JJ; Cassinat B; Chevret S; Turlure P; Cambier N; Roussel M; Bellucci S; Grandchamp B; Chomienne C; Fenaux P
Blood; 2008 Oct; 112(8):3065-72. PubMed ID: 18650451
[TBL] [Abstract][Full Text] [Related]
22. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G;
Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737
[TBL] [Abstract][Full Text] [Related]
23. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
24. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
Mascarenhas J; Kosiorek H; Prchal J; Yacoub A; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Salama ME; Weinberg RS; Rampal R; Goldberg JD; Mesa R; Dueck AC; Hoffman R
Leukemia; 2019 Dec; 33(12):2974-2978. PubMed ID: 31363161
[No Abstract] [Full Text] [Related]
25. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
26. Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance.
Chiaranairungrot K; Kaewpreechawat K; Sajai C; Pagowong N; Sukarat N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L; Rattarittamrong E
Hematology; 2022 Dec; 27(1):813-819. PubMed ID: 35894859
[TBL] [Abstract][Full Text] [Related]
27. Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy.
Li Y; Zhu J; Ding B
Int J Clin Oncol; 2013 Oct; 18(5):922-6. PubMed ID: 22898909
[TBL] [Abstract][Full Text] [Related]
28. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
Sever M; Newberry KJ; Verstovsek S
Leuk Lymphoma; 2014 Dec; 55(12):2685-90. PubMed ID: 24524340
[TBL] [Abstract][Full Text] [Related]
30. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
31. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
Girodon F; Schaeffer C; Cleyrat C; Mounier M; Lafont I; Santos FD; Duval A; Maynadié M; Hermouet S
Haematologica; 2008 Nov; 93(11):1723-7. PubMed ID: 18728027
[TBL] [Abstract][Full Text] [Related]
32. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
33. Ropeginterferon alfa-2b for the treatment of patients with polycythemia vera.
Wagner SM; Melchardt T; Greil R
Drugs Today (Barc); 2020 Mar; 56(3):195-202. PubMed ID: 32282866
[TBL] [Abstract][Full Text] [Related]
34. Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
Masarova L; Yin CC; Cortes JE; Konopleva M; Borthakur G; Newberry KJ; Kantarjian HM; Bueso-Ramos CE; Verstovsek S
Exp Hematol Oncol; 2017; 6():30. PubMed ID: 29152412
[TBL] [Abstract][Full Text] [Related]
35. Essential Thrombocythemia and Polycythemia Vera: Focus on Clinical Practice.
Tefferi A; Barbui T
Mayo Clin Proc; 2015 Sep; 90(9):1283-93. PubMed ID: 26355403
[TBL] [Abstract][Full Text] [Related]
36. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
37. [Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera].
Sokolova MA; Turkina AG; Melikian AL; Sudarikov AB; Treglazova SA; Shukhov OA; Gemdzhian EG; Abdullaev AО; Kovrigina AM; Misyurin AV; Pliskunova YV; Ivanova VL; Moiseeva TN
Ter Arkh; 2016; 88(12):69-77. PubMed ID: 28139563
[TBL] [Abstract][Full Text] [Related]
38. Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
Verger E; Cassinat B; Chauveau A; Dosquet C; Giraudier S; Schlageter MH; Ianotto JC; Yassin MA; Al-Dewik N; Carillo S; Legouffe E; Ugo V; Chomienne C; Kiladjian JJ
Blood; 2015 Dec; 126(24):2585-91. PubMed ID: 26486786
[TBL] [Abstract][Full Text] [Related]
39. Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.
Them NC; Bagienski K; Berg T; Gisslinger B; Schalling M; Chen D; Buxhofer-Ausch V; Thaler J; Schloegl E; Gastl GA; Wolf D; Strecker K; Egle A; Melchardt T; Burgstaller S; Willenbacher E; Zagrijtschuk O; Klade C; Greil R; Gisslinger H; Kralovics R
Am J Hematol; 2015 Apr; 90(4):288-94. PubMed ID: 25545244
[TBL] [Abstract][Full Text] [Related]
40. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Spanoudakis E; Bazdiara I; Kotsianidis I; Margaritis D; Goutzouvelidis A; Christoforidou A; Tsatalas C; Bourikas G
Ann Hematol; 2009 Jul; 88(7):629-32. PubMed ID: 19096846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
